Skip to main content

Table 2 Schedule of events

From: Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study

Visits

Baseline day 1

Baseline day 2

Month 3a ± 21 days

Month 6b

 ± 21 days

Month 12

 ± 21 days

Informed consent

X

    

Demographic information

X

    

Medical and surgical history

X

    

Inclusion exclusion

X

    

Vital signs

X

X

X

X

X

Physical exam

Xc

Xc

X

X

X

Pregnancy testd

X

 

X

X

X

10 Meter walk

X

    

100 m timed

X

X

X

X

X

NSAD

X

X

X

X

X

4 stair climb

X

X

X

X

X

Timed Up and Go (TUG)

X

X

X

X

X

Handheld dynamometry

X

X

X

X

X

Performance Upper Limb PUL 2.0

X

X

X

X

X

9 hole peg test

X

X

X

X

X

Spirometry

X

X

X

X

X

Concomitant meds

X

X

X

X

X

Domain delta questionnaire

 

X

X

X

X

Patient reported outcome measures

Xc

Xc

X

X

X

Urine biomarkers

 

X

 

X

X

Blood biomarkers

 

X

X

X

X

Prior muscle biopsy acquired (if performed)

X

    

Review adverse events

 

X

X

X

X

  1. aFor individuals with SGCA-G pathogenic variants
  2. bn/a to DNAJB6/ LGMDD1cohort
  3. cAssessment can occur on baseline day 1 or baseline day 2
  4. dPregnancy test for women of childbearing potential